Annals of Clinical Pathology

Cite this article: Corti M, Pavlosky A, Narbaitz M (2020) Primary Gastric Non-Hodgkin Lymphoma as Second AIDS-Defining Malignancy in a Patient under HAART. Ann Clin Pathol 7(1): 1154.

CentralBringing Excellence in Open Access

*Corresponding author

Marcelo Corti, Division of HIV/AIDS, Infectious Diseases F. J. Muñiz Hospital, Puán 381, 2°floor, Buenos Aires, Argentina, Email: marcelocorti@fibertel.com.ar

Submitted: 01 September 2020

Accepted: 14 September 2020

Published: 15 September 2020

ISSN: 2373-9282

Copyright© 2020 Corti M, et al.

OPEN ACCESS

Keywords• Primary gastric lymphoma; Diffuse large B cell

lymphoma; AIDS; HIV

Case Report

Primary Gastric Non-Hodgkin Lymphoma as Second AIDS-Defining Malignancy in a Patient under HAARTMarcelo Corti1*, Astrid Pavlosky2, and Marina Narbaitz3

1Division of HIV/AIDS, Muñiz Hospital, Argentina1Department of Medicine, University of Buenos Aires, Argentina2Medical Director, Pavlosky Hematology Center, Argentina3National Academy of Medicine, Histopathology Laboratory, Argentina

Abstract

Primary gastric non-Hodgkin lymphoma is a severe complication during the clinical course of human immunodeficiency virus infection. Clinical presentation includes symptoms associated with the upper digestive tract and “B” symptoms (fever, night sweats and weight loss). Endoscopic findings can reveal polypoid, ulcero-infiltrative or ulcer lesions. Multiple biopsy smears are necessary to determine histopathological subtypes. Diffuse large B cell lymphoma (DLBCL) is the most common histopathological subtype in HIV/AIDS patients followed by Burkitt’s lymphoma and plasmablastic lymphoma. Chemotherapy plus highly active antiretroviral therapy is the best treatment to achieve a complete remission with prolonged survival in this kind of patients.

Here we present an HIV seropositive patient who developed a primary gastric DLBCL as second AIDS-defining neoplasm during HAART therapy and after three years of successfully controlling HIV-viral load. Patient presented with a past history of anal squamous cell carcinoma several years before and gastro esophageal reflux disease treated for a long time with omeprazole. He presented with epigastric pain, nausea and dyspepsia. Upper gastrointestinal endoscopy showed erosive gastritis and a large gastric ulcer at the minor gastric curvature. Microscopy examination and immunohistochemistry of the biopsy smears of the large ulcer biopsy confirm the diagnosis of primary gastric DLBCL. He was treated with HAART plus chemotherapy with a complete remission for a time of three years.

INTRODUCTIONNon-Hodgkin lymphoma (NHL) is a common complication

of the disease caused by the human immunodeficiency virus (HIV). The involvement of the digestive tract, from the oral cavity to the anus region, is very frequent [1,2]. One of the most common characteristic of AIDS-associated NHL is the extranodal compromise at the time of diagnosis. Gastrointestinal tract (GIT) is the most commonly site of primary extranodal lymphomas, including 40% to 50% of all cases [3-6].

In the GIT, stomach is the most frequent site of involvement (50% to 88%) followed by the small intestine (14% to 38%) and the colon (10% to 20%) [4-7,8]. GIT involvement is also frequent in HIV-infected patient’s account 15% to 75% of all cases [9-11].

Here we present a patient infected with HIV who developed a primary gastric NHL during highly active antiretroviral therapy (HAART) with immune reconstitution and undetectable viral load. Patient was treated with the same scheme of HAART plus chemotherapy with a prolonged survival and a complete remission of the lymphoproliferative disorder.

CASE REPORTA 64-year-old man with a large history of HIV infection and

under HAART presented with unspecific abdominal symptoms of a month of evolution. The patient referred episodic epigastric pain, postprandial fullness, nausea, eructation and breathe odor. He denied history of fever and night sweats but the clinical manifestations were associated with a weight loss of 5 kg. The patient had history of a numerous episodes of H. pylori infection and erosive/ulcerative gastritis. He was treated in all episodes with different antimicrobial regimens. Six years before, on antiretroviral treatment, with undetectable viral load and immunological reconstitution, he was diagnosed with intra-anal squamous cell carcinoma associated with HPV-16. He was treated with HAART plus chemotherapy based on Nigro’s scheme plus tridimensional radiotherapy with a complete remission and without relapse during 10 years.

Her physical examination revealed no abdominal findings, no hepatomegaly, no splenomegaly and no lymphadenopathy. Laboratory tests were normal including LDH levels. The CD4-T-cell count was 173 cells/uL and the plasma viral load was undetectable. Upper gastrointestinal endoscopy was done and

Corti M, et al. (2020)

Ann Clin Pathol 7(1): 1154 (2020) 2/4

CentralBringing Excellence in Open Access

showed erosive/ulcerative gastritis at the gastric roof and body. Additionally, a large gastric ulcer at the minor gastric curvature was observed (Figure 1). Several biopsy smears were taken and revealed a chronic and active gastritis with H. pylori infection positive. Microscopy examination of the biopsy smears of the large ulcer biopsy showed a dense proliferation of atypical lymphoid cells, of median and large-sized, eosinophilic cytoplasm and one or various nucleoli infiltration of submucosa and muscularis propriety (Figures 2 and 3). Immunohistochemistry revealed that neoplastic cells were positive for CD20 (Figure 4), BcL2 (+) with negative CD3 (Figure 5) and a Ki67 proliferation index of 30% (Figure 6). Cytokeratin was also negative. Final histopathological diagnosis was primary gastric diffuse large B cell lymphoma (DLBCL). Thorax and abdominal tomography scan to determine clinical stage were normal. Bone marrow biopsy was done to stage the disease and was negative to atypical lymphoid infiltration. He was treated with the same scheme of HAART based on tenofovir plus emtricitabine, dolutegravir and darunavir boosted with ritonavir. Additionally, he received 6 cycles of chemotherapy based on CHOP plus rituximab. Also, he received trimethoprim-sulfamethoxazole as primary prophylaxis for Pneumocystis jiroveci; granulocyte colony stimulating factor, fluconazole and levofloxacin in each cycle.

After 3 years of complete remission the patient developed a new primary gastric DLBCL currently under chemotherapy and antiretroviral treatment.

DISCUSSIONSeveral recent studies have been reported an increased

incidence of both Hodgkin lymphoma and NHL in AIDS patients. These patients, infected with HIV, are at high risk to develop NHL. The risk of NHL is 100 to 300-fold higher in HIV infected patients in comparison with the general population [11], being this the second most frequent malignancy following Kaposi´s sarcoma [12]. Primary gastrointestinal NHL is a distinct clinic-pathological entity. Lymphomas represent only the 2% to 5% of all gastric malignant tumors. The increase in the incidence of primary gastric lymphoma (PGL) in the last decades is related with the increase in the number of immunodeficiency patients, especially those with HIV infection. Hernandez JA et al [13], detected 15 patients with

PGL in a series of 76 patients with HIV-AIDS-related NHL. NHL of extranodal sites, as the digestive tract, is considered as primary when the extranodal compromise is equal or greater compared with the nodal involvement [14]. More than 90% of PGNHL are of B-cell phenotype and generally is not associated with peripheral adenopathy [13]. Clinical findings include abdominal pain, epigastric pain, early satiety, nausea, vomiting, gastrointestinal bleeding and B symptoms as fever, weight loss and night sweets. Generally, the endoscopic findings include thickening of gastric folds, tumor lesions, polypoid lesions, ulcerative lesions or the combination of these [2,16]. Fontes Rezende et al [2], in a series of 243 HIV-seropositive patients evaluated with upper digestive endocopic detected 6 patients (2,5%) with PGL. The endoscopic findings include the involvement of gastric body in all cases, with compromise of the fundus in 3 cases and also the gastric antrum in 2 others.

Histopathological biopsy smears must be classified according with the Real and WHO classification [17]. Ann Arbor

Figure 1 Endoscopic findings at initial diagnosis showed a large ulcerated lesion at the minor gastric curvature (white arrow).

Figure 2 Histology with H-E stain on the biopsy (×100) showing diffuse infiltration of submucosa and muscularis propria by lymphoid neoplasm.

Figure 3 H-E (x 400) showing large atypical lymphoid cells with indented vesicular type of nucleus, prominent nucleoli, with scanty eosinophilic cytoplasm and atypical mitosis.

Corti M, et al. (2020)

Ann Clin Pathol 7(1): 1154 (2020) 3/4

CentralBringing Excellence in Open Access

classification with Mussohoff modification is used to the staging of gastric lymphomas in I to IV stadiums. The IIA include gastric lymphomas with proximal lymphatic nodules involvement and IIB when the neoplasm also infiltration the distal nodal lymphatic [18].

Generally, AIDS-associated NHL are a high grade lymphomas including DLBCL, Burkitt´s lymphoma (BL) and plasmablastic lymphoma (PBL), as most frequent subtypes and which are considered as an AIDS-defining illnesses [19]. These patients are associated with a rapid progression of neoplasm disease, frequent extranodal initial manifestations, poor prognosis and a short survival after diagnosis [20].

In the stomach, it is possible to show other type of lymphomas, named as mucosa-associated lymphoid tissue (MALT) lymphoma. MALT lymphoma is a low grade marginal zone B-cell lymphoma strongly associated with Helicobacter pylori infection in his pathogenesis. MALT lymphoma can occur at different extranodal sites as the GIT. Within de gastric NHL, MALT lymphoma include

around 60% and most of them has a better prognosis and regressed after H. pylori eradication treatment alone. Localized gastric DLBCL do not regress with the H. pylori treatment and eradication and need 4 to 6 cycles of chemotherapy [21].

Actually, the best treatment of NHL in AIDS patients is based on the combination of highly active antiretroviral therapy (HAART) plus chemotherapy [22,23]. The survival of patients with AIDS-related NHL is significantly longer compared with the pre-HAART era, with high rates of complete remission and prolonged response to HAART, as we can see in our patient [14,15]. Prolonged survival is significantly associated with achievement of a complete remission and a good virological response to HAART [24]. In comparison with a median survival of 7 months after NHL diagnosis in the pre-HAART era, the survival is prolonged in the post-HAART period [25,26]. HAART plus high intensity multi-agent chemotherapeutic regimens including the anti-CD20 monoclonal antibody rituximab is associated with a high remission rate in HIV associated-NHL [27]. The role of surgery is limited to cases of obstruction or uncontrollable bleeding. The spontaneous remission of aggressive lymphomas as DLBCL is extremely rare. Gattiker et al [28], in a retrospectively review of 209 cases of aggressive lymphomas including 69 cases of DLBCL showed no case of spontaneous remission of DLBCL. Watari et al [29], reported 2 cases of remission of gastric DLBCL without any treatment. Finally, Sugiyama et al [30], published a case of gastric DLBCL with a large spontaneous remission for 10 years. Also, in the setting of HIV infection, it is possible to show a complete remission of NHL associated with HAART [31]. In this stage, is possible that the immune reconstitution based on HAART can play a role in the tumor remission without chemotherapy.

In conclusion, HIV-positive patients have a high risk to develop lymphomas, especially NHL. Nevertheless, the risk has dropped gradually in the HAART era, especially in those with undetectable viral load and immune restoration.

REFERENCES1. Corti M. HIV/AIDS and Cancer: The Hidden Epidemic. Clin Oncol.

2019; 4: 1622-1623.

Figure 4 Immunohistochemical staining revealed large atypical lymphoid cells positive by CD20 antibody.

Figure 5 Negative immunohistochemical staining of lymphoma cells by CD3 antibody.

Figure 6 Ki 67 showed a high proliferation index.

Corti M, et al. (2020)

Ann Clin Pathol 7(1): 1154 (2020) 4/4

CentralBringing Excellence in Open Access

2. Fontes Rezende RF, Mantelmacher M, da Costa Ferreira S, Hyppólito EB, Machado AA, Ardengh JC, et al. Clinical, endoscopic and prognostic aspects of primary gastric Non-Hodgkin’s lymphoma associated with acquired immunodeficiency syndrome. Bras J Infect Dis. 2009; 13: 2-4.

3. Zucca E, Rogero OE, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part I: gastrointestinal, cutaneous and genitourinry lymphomas. Ann Oncol. 1997; 8: 727-737.

4. Galindo F, Fernández Marty P, Kogan A, Díaz S, Barugel ME, Dos Santos R. Linfomas de intestino delgado y cirugía. Rev Argent Cirug. 1996; 70: 157-167.

5. Thieblemont C, Bastion Y, Berger F, Rieux C, Salles G, Dumontet C, et al. Mucosa-associated lymphoid tissue gastrointestinal and nongastrointestinal lymphoma behavior. Analysis of 108 patients. J Clin Oncol. 1997; 15: 1624-1630.

6. Nakamura S, Matsumoto T, Lida M, Yao T, Tsuneyoshi M. Primary gastrointestinal lymphoma in Japan: A clinicopathologic analysis of 455 patients with special reference to the time trends. Cancer. 2003; 97: 2462-2473.

7. Boddie AW, Mullins JD, West G, Bouda D. Extranodal lymphoma: surgical and other therapeutic alternatives. Curr Probl Cancer. 1982; 6: 1-63.

8. Danzig JB, Brandt LJ, Reinus JF, Klein RS. Gastrointestinal malignancy in patients with AIDS. Am J Gastroenterol 1991; 86: 715-718.

9. Heise W, Arastéh K, Mostertz P, P Mostertz, J Skörde, W Schmidt, C Obst, et al. Malignant gastrointestinal Lymphomas in patients with AIDS. Digestion. 1997; 58: 218-224.

10. Levine A.M. Lymphoma in acquired immunodeficiency syndrome. Semin Oncol. 1990; 17: 104-112.

11. Hodgkin and Non-Hodgkin lymphomas. In: Edge SB, Byrd DR, Compton CC, et al. (Edn). AJCC Cancer Staging Manual. 7thedn, New York, NY: Springer, 2010.

12. Cornejo-Juárez P, Volkow-Fernández P, Avilés-Salas A, Calderón-Flores E. AIDS and non-Hodgkin´s lymphoma. Experience at an oncological center in Mexico. Rev Invest Clin. 2008; 60: 375-381.

13. Hernández JA, Navarro JT, Ribera JM, Sancho JM, Vaquero M, Sirera G, et al. Primary gastrointestinal lymphoma in patients infected with HIV: Study of 15 cases in a series of 76 patients with non-Hodghkin’s limphoma and HIV infection. Med Clin (Barc). 1999; 112: 222-224.

14. D’Amore F, Christensen BE, Brincker H, N T Pedersen, K Thorling, J Hastrup, et al. Clinico-pathological features and prognostic factors in extranodal extranodal non-Hodgkin’s lymphomas. Eur J Cancer. 1991; 27: 1201-1208.

15. Atalay C, Kanlioz M, Demir S, Pak I, Altinok M. Primary gastrointestinal tract lymphomas. Acta Chir Belg 2003; 103: 616-620.

16. Arista NJ, Jimenez A, Keirns C, Larraza O, Larriva J. The role of endoscopy biopsy in the diagnosis of gastric lymphoma: A morphological and immunohistochemichal eter aisal. Hum Pathol. 1991; 22: 339-348.

17. Harris NL, Jaffe ES, Stein H, P M Banks, J K Chan, M L Cleary, et al. A Revised European-American Classification of Lymphoid Neoplasms:

A Proposal from the International Lymphoma Study Group. Blood. 1994; 84: 1361-1392.

18. Carbone PP, Kaplan HS, Musshoff K, DW Smithers, M Tubianaet al. Report of the committee on Hodgkin´s Disease Staging Procedures. Cancer Res. 1971; 31: 1860-1861.

19. Corti M, De Dios Soler M, Baré P, María F Villafañe, Miguel De Tezanos Pinto, Raúl Perez Bianco, et al. AIDS related lymphomas: histopathological subtypes and association with Epstein Barr and human herpes virus type-8. Medicina (Buenos Aires). 2010; 70: 151-158.

20. Akanmu, A S. AIDS-associated malignancies. Afr J Med Med Sci. 2006; 35: 57-70.

21. Nakamura S, Sugiyama T, Matsumoto T, Iijimo K, Ono S, Tajika M, et al. Long term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow up study of 420 patients in Japan. Gut. 2012; 61: 507-513.

22. Vaccher E, Spina M, di Gennaro G, R Talamini, G Nasti, O Schioppa, G Vultaggio, et al. Concomitant CHOP chemotherapy and highly active antiretroviral therapy in patients with HIV-related non-Hodgkin´s lymphoma. Cancer. 2001; 91: 155-163.

23. Ratner L, Lee J, Tang S, F Hamzeh, B Herndier, D Scadden, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodkin´s lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001; 91: 2171-2178.

24. Wolf T, Brodt HR, Fichtlscherer S, Mantzsch K, Hoelzer D, Helm EB, et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin′s lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymph. 2005; 46: 207-215.

25. Chow KU, Mitrou PS, Geduldig K, Helm EB, Hoelzer D, Brodt HR. Changing incidence and survival in patients with AIDS-related non-Hodgkin´s lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma. 2001; 41: 106-116.

26. Hoffmann C, Wolf E, Fatkenheuer G, Buhk T, Stoehr A, Plettenberg A, et al. Response to highly active antiretroviral therapy strongly predicts outcome in patients with AIDS-related lymphoma. AIDS. 2003; 17: 1521-1529.

27. Bustamante-Bernal M, Galvis J, Matos D, Sosa O, Syed SH, Padilla O, et al. Burkitt´s Lymphoma of the rectosigmoid and the stomach presenting as hematochezia. Am J Case Rep. 2016; 15: 89-92.

28. Gattiker HH, Wiltshaw E, Galton DA. Spontaneous regression in non-Hodgkin’s lymphoma. Cancer. 1980; 45: 2627-2632.

29. Watari J, Saitoh Y, Fujiya M, Nakamura K, Inaba Y, Okamoto K, et al. Spontaneous remission of primary diffuse large B-cell gastric lymphoma. J Gastroenterol. 2005; 40: 414-420.

30. Sugiyama T, Arita K, Shinnob E, Nakajima T. Spontaneous remission of diffuse large B cell lymphoma in the stomach and the continuation of remission for 10 years. Case Rep Gastroenterol. 2018; 12: 699-703.

31. Khan F, Bauer F, Gazi G, Bilgrami S. Regression of large B-cell non-Hodgkin´s lymphoma of stomach with HAART: Case report and review. Leuk Lymphoma. 2006; 47: 750-754.

Corti M, Pavlosky A, Narbaitz M (2020) Primary Gastric Non-Hodgkin Lymphoma as Second AIDS-Defining Malignancy in a Patient under HAART. Ann Clin Pathol 7(1): 1154.

Cite this article